Abbott Laboratories, the manufacturers of ritonavir-boosted lopinavir (Kaletra) announced the development of a new tablet formulation of the protease inhibitor on July 27th at the Third International ...

LIVMARLI Tablet formulation approved for patients with Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) ...

Chewable tablets have also found application in veterinary medicines. This paper reviews considerations for the formulation of chewable tablets including sensory characteristics, chewability ...

Actinogen Medical Limited (ASX: ACW) announces that a recent trial designed to confirm therapeutic blood levels of the ...

The tablet formulation of Brukinsa is supplied as a 160mg dose, allowing patients the convenience of taking only 2 tablets daily. The Food and Drug Administration (FDA) has approved a new tablet ...

The new tablet formulation maintains BRUKINSA’s dosing flexibility by providing patients and prescribers with the option of once- or twice-daily dosing and is designed to simplify management of ...

The authors investigated the effects of formulation and processing parameters on floating matrix-controlled drug-delivery systems.

The European Commission has approved a new film-coated tablet formulation of Sino-American oncology-focused biotech BeOne Medicines’ Brukinsa (zanubrutinib) for all approved indications.

SAN CARLOS, Calif., June 11, 2025--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has ...

BeOne Medicines recently announced that the European Commission approved a new film-coated tablet formulation of BRUKINSA (zanubrutinib) for all existing indications, halving the required daily pill ...

BeOne Medicines Ltd., a global oncology company, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending ...